Blueprint Medicines Revenue Growth Rates (BPMC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Blueprint Medicines Corporation  (NASDAQ: BPMC)
 

BPMC's Revenue Growth by Quarter and Year

Blueprint Medicines's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BPMC Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 149.41
FY 149.41

BPMCs Annual Revenue
Blueprint Medicines's Revenue in the fiscal year 2024 $ 508.82 millions
Blueprint Medicines's Revenue in the fiscal year 2023 $ 249.38 millions
Blueprint Medicines's Revenue in the fiscal year 2022 $ 187.27 millions
Blueprint Medicines's Revenue in the fiscal year 2021 $ 182.47 millions
Blueprint Medicines's Revenue in the fiscal year 2020 $ 800.33 millions




BPMC Revenue first quarter 2025 Y/Y Growth Comment
Blueprint Medicines Corporation reported Revenue rise of 55.44% year on year in the first quarter 2025, to $ 149.41 millions, this is lower than Blueprint Medicines Corporation's recent average Revenue surge of 377.1%.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Revenue growth. While Blueprint Medicines Corporation' s Revenue jump of 55.44% ranks overall at the positon no. 305 in the first quarter 2025.


BPMC Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 88.18 % 163.3 % -72.52 %
3rd Quarter September - 126.59 % -1.75 % 132.74 %
2nd Quarter June - 139.99 % 55.72 % 32.37 %
1st Quarter March 55.44 % 67.25 % -9.02 % 183.15 %
FY   - 104.03 % 33.18 % -

Financial Statements
Blueprint Medicines's first quarter 2025 Revenue $ 149.41 millions BPMC's Income Statement
Blueprint Medicines's first quarter 2024 Revenue $ 96.12 millions Quarterly BPMC's Income Statement


BPMC Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 14.19 % 37.49 % -48.7 %
3rd Quarter September - -7.22 % -1.74 % 55.75 %
2nd Quarter June - 43.74 % 0.17 % -41.48 %
1st Quarter March 2.08 % 23.58 % 94.55 % -41.23 %
FY (Year on Year)   - 104.03 % 33.18 % -


Back to BPMC Growth rate Comparisons >> Back to BPMC Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #98
Overall #305

Revenue Y/Y Growth Statistics
High Average Low
8066 % 377.1 % -96.68 %
(Dec 31 2020)   (Jun 30 2019)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #98
Overall #305
Revenue Y/Y Growth Statistics
High Average Low
8066 % 377.1 % -96.68 %
(Dec 31 2020)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Blueprint Medicines's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
7416.28 % 361.09 % -100 %
(Sep 30 2020)  


BPMC's I. Quarter Q/Q Revenue Comment
Blueprint Medicines Corporation achieved in the I. Quarter 2025 below company average Revenue growth of 2.08% quarter on quarter, to $ 149.41 millions.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue quarter on quarter growth. While Blueprint Medicines's Revenue growth quarter on quarter, overall rank is 1282.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #192
Overall #1282
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #192
Overall #1282
Revenue Q/Q Growth Statistics
High Average Low
7416.28 % 361.09 % -100 %
(Sep 30 2020)  


BPMC's I. Quarter Q/Q Revenue Comment
Blueprint Medicines Corporation achieved in the I. Quarter 2025 below company average Revenue growth of 2.08% quarter on quarter, to $ 149.41 millions.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue quarter on quarter growth. While Blueprint Medicines's Revenue growth quarter on quarter, overall rank is 1282.


Blueprint Medicines's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 562.12 $ 508.82 $ 440.23 $ 368.62 $ 288.03
Y / Y Revenue Growth (TTM) 95.16 % 104.04 % 118.86 % 82.34 % 58.64 %
Year on Year Revenue Growth Overall Ranking # 225 # 86 # 830 # 847 # 2187
Seqeuential Revenue Change (TTM) 10.47 % 15.58 % 19.43 % 27.98 % 15.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 833 # 153 # 566 # 252 # 761


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Blueprint Medicines's cumulative twelve months Revenue were $ 562 millions, company would post below average annual Revenue growth of 15.5% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Blueprint Medicines's Revenue growth from the 146.37% growth in Dec 31 2024.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 86 to 225.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 59
Overall # 225

Revenue TTM Y/Y Growth Statistics
High Average Low
806.5 %
 126.29 %
-145.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 189
S&P 500 # 833
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Blueprint Medicines's cumulative twelve months Revenue were $ 562 millions, company would post below average annual Revenue growth of -145.14% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Blueprint Medicines's Revenue growth from the 146.37% growth in Dec 31 2024.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 86 to 225.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 59
Overall # 225

Revenue TTM Y/Y Growth Statistics
High Average Low
806.5 %
126.29 %
-145.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 189
S&P 500 # 833




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BPMC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Krystal Biotech Inc 94.88%$ 94.880 millions
Avadel Pharmaceuticals Plc94.83%$ 94.830 millions
Scpharmaceuticals Inc 92.59%$ 92.593 millions
Tg Therapeutics Inc 90.40%$ 90.402 millions
Cytokinetics Incorporated89.10%$ 89.102 millions
Aclarion Inc 87.77%$ 87.769 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Neuronetics Inc 85.73%$ 85.733 millions
2seventy Bio Inc 84.46%$ 84.463 millions
Optinose Inc 83.27%$ 83.266 millions
Profound Medical Corp 82.14%$ 82.140 millions
Rigel Pharmaceuticals Inc80.58%$ 80.582 millions
Sarepta Therapeutics Inc 80.15%$ 80.150 millions
Sage Therapeutics Inc 77.97%$ 77.968 millions
Atara Biotherapeutics Inc 77.85%$ 77.854 millions
Evoke Pharma Inc 77.48%$ 77.481 millions
Vsee Health Inc 76.43%$ 76.433 millions
Vivosim Labs Inc 75.86%$ 75.862 millions
Akebia Therapeutics Inc 75.84%$ 75.840 millions
Catheter Precision Inc 74.39%$ 74.390 millions
Nexgel Inc 72.83%$ 72.828 millions
Kiniksa Pharmaceuticals International Plc72.54%$ 72.538 millions
Seer Inc 72.00%$ 72.003 millions
Crispr Therapeutics Ag71.63%$ 71.627 millions
Elite Pharmaceuticals Inc 68.92%$ 68.922 millions
Therapeuticsmd Inc 67.95%$ 67.949 millions
Avita Medical Inc 66.73%$ 66.733 millions
Schrodinger Inc 65.93%$ 65.926 millions
Assembly Biosciences Inc 62.82%$ 62.818 millions
Axsome Therapeutics Inc 61.95%$ 61.953 millions


About Blueprint Medicines Revenue Growth Rates (BPMC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Blueprint Medicines Corp (CIK 1597264).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-25-006108
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Blueprint Medicines Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.